Disc Medicine (IRON) is a clinical-stage biopharmaceutical company. Disc Medicine (IRON) has built deep expertise in the role of iron homeostasis in hematologic disorders. The biotech company is expanding their portfolio with these highly complementary antibody programs. CEO John Quisel weighs in on agreeing to pay $10M to Mabwell Therapeutics as a down payment.
23 Jan 2023
Market On Close
07 Jul 2023
Morning Trade Live
15 Sep 2023
Next Gen Investing
05 Jul 2023
Morning Trade Live
08 Sep 2023
The Watch List
02 Oct 2023
The Watch List
21 Sep 2023